RxDoctor Payments Data

Kenneth Laurora, MD

Internal Medicine · Livingston, TXNPI 1184606378

Payments from drug & device makers

$692in general payments, 2019–2025

Across 36 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$286
  • Pfizer$91
  • Mylan Specialty L.p.$77
  • Otsuka America Pharmaceutical, Inc.$46
  • Novartis$43
  • GSK$38
  • plus $112 from 5 others

What the payments were for

  • Food & beverage$692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$692 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,554
Medicare patients
132
Services billed
1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin120$109,240
EliquisApixaban66$63,366
TrulicityDulaglutide44$54,323
MounjaroTirzepatide25$36,791
FarxigaDapagliflozin Propanediol30$35,370
XareltoRivaroxaban23$31,514
OzempicSemaglutide28$26,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$19,826
JanuviaSitagliptin Phosphate14$18,995
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$16,436
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$14,998
BrilintaTicagrelor11$12,965
Repatha SyringeEvolocumab20$12,598
Breo ElliptaFluticasone/Vilanterol20$11,437
MyrbetriqMirabegron11$8,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$286$94,20289 claims
PfizerEliquis$91$63,36666 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$38$39,12849 claims
Novo NordiskOzempic$36$26,25328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Livingston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →